Jietao Ma
Shenyang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized Trials.
Journal: JCO precision oncology
Published: July 10, 2025
Comparative efficacy of first-line therapies for PD-L1-negative advanced NSCLC: A network meta-analysis with reconstructed survival curves.
Journal: Critical reviews in oncology/hematology
Published: May 12, 2025
Immunotherapy-Boosted Stereotactic Ablative Radiotherapy in Inoperable Early-Stage Non-Small Cell Lung Cancer.
Journal: Current treatment options in oncology
Published: April 14, 2025
Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells.
Journal: Molecular cancer
Published: September 26, 2024
First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.
Journal: Scientific reports
Published: July 30, 2024
Impact of Prophylactic Use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced NSCLC: A Cohort Study.
Journal: JTO clinical and research reports
Published: July 10, 2024
Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs.
Journal: Therapeutic advances in medical oncology
Published: May 16, 2024
Impact of Drp1-regulated changes in T cell activity on the combined antitumor effects of PARPi and PD-1 inhibitors.
Journal: International immunopharmacology
Published: January 06, 2024
Enhanced T cell immune activity mediated by Drp1 promotes the efficacy of PD-1 inhibitors in treating lung cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: October 06, 2023
Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 31, 2023
Impact of Drp1-Mediated Mitochondrial Dynamics on T Cell Immune Modulation.
Journal: Frontiers in immunology
Published: February 11, 2022
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 31, 2021
Last Updated: 09/26/2026